Jul 2026· Asian Pacific Journal of Cancer Biology· 0 citations· 31 references
TL;DR
The study suggests that the inhibition of the Wnt/LEF1 axis is associated with the potential activation of a compensatory survival mechanism, involving the NF-kappa B/AP-1 pathway.
Abstract
Background: Chronic lymphocytic leukemia (CLL) remains a major clinical challenge, mainly due to the persistent drug resistance of leukemia- affected cells targeted therapies. The transcription factor gene LEF1, and its governing Wnt/β-catenin axis, is is a well-established driver as a fundamental driver promoting cellular growth and proliferation in this malignancy consequently that we designed this current study to identify the precise compensatory survival mechanism employed by CLL cells following successful disruption of LEF1 signaling.
Methods: Gene expression data were obtained from the GEO database (GSE299964) to study and analyzed LEF1inhibition in CLL cell. Differential expression analysis (DEA) and pathway enrichment analysis were used to identify inhibited and activated pathways also was designed a protein-protein interaction network (PPI) to identify and visualize the interaction. Statistical analyses were performed within the R environment (version 4.4.1).
Results: By used DEA, the results showed significant inhibition of the Wnt axis (LEF1, Log2FC: -6.22) and concurrent activation of the NF-κB/AP-1 pathway, particularly SLC3A2 (+3.59) and JUN (+3.10). And downregulation in key growth factors was observed specifically CCND1 and MYC. In contrast, the pathway enrichment analysis suggested strong statistical of the NF-kappa B, and an increase in the transcription factors was observed NFKB1 and JUN. It is important that the visualization of the PPI network provided visual evidence the existence of direct regulatory links connecting suppressed Wnt genes to activated NF-kappa B genes, this suggesting a potential emerging therapeutic dependency.
Conclusion: The study suggests that the inhibition of the Wnt/LEF1 axis is associated with the potential activation of a compensatory survival mechanism, involving the NF-kappa B/AP-1 pathway. These results indicate that chronic lymphocytic leukemia cells this reciprocal interaction may be used as an adaptive immune response to the disruption of the primary pathway. This aggregation strategy may represent a promising way to address anticipated resistance mechanisms, although further functional and laboratory studies are needed to validate them.
It is reported that an unappreciated RNA-binding protein, Rbm5, selectively promotes murine leukemogenesis, maintains LSC self-renewal in vivo, and is dispensable for normal hematopoiesis.
FZD5 is a TAM-enriched marker in glioma tissues and a potential regulator of macrophage-associated immunosuppressive programs, supporting its utility as a prognostic biomarker and a candidate target for microenvironment-oriented interventions in glioma.
Cobicistat, a candidate MEST-inhibitory compound, exhibits favorable preclinical efficacy and safety, providing a promising candidate for targeted GC therapy, and functions as a key oncoprotein driving GC progression via NF-κB activation.
Hong-Tai Cao, Huili Ye, Wen-Tao Zhang et al.· Frontiers in Oncology· 0 citations
The findings expand the understanding of the chromatin complexes required to maintain a de-differentiated state in neuroblastoma and suggest the therapeutic potential for USP7 inhibitors in the treatment of neuroblastoma.
Nathaniel W. Mabe· Clinical Cancer Research· 0 citations
Genome-wide CRISPR screens have systematically identified genes required for cancer cell survival, yet these studies are typically performed under standardized conditions that do not fully recapitulate the physiological stresses encountered within the tumor microenvironment. In a recent issue of Nature Genetics, Cherui...
Zihan Ning, Guangchuan Wang· Cancer Research· 0 citations
Pyroptosis plays a crucial role in the prognosis of LUSC, and this effect is associated with differential NOD1 expression in M2 macrophages, emphasizing a potential candidate target for tumor immunoregulation-based strategies.
Taihao Wang, Wei Zhang, Zhihao He et al.· Frontiers in Cell and Develo...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.